Age at diagnosis (years)
|
30.95 ± 13.88
|
32.65 ± 14.61
|
0.469
|
34.19 ± 14.14
|
39.42 ± 15.15
|
0.086
|
Gender (male to female)
|
8:48
|
13:101
|
0.624
|
2:27
|
17:141
|
0.765
|
Recurrence time or follow-up timea (months)
|
21.82 (13.39, 31.59)
|
19.23 (10.02, 34.32)
|
0.440
|
26.43 (16.72, 41.97)
|
22.92 (11.63, 43.65)
|
0.361
|
Duration of serological activity/inactivity before SACQ/SQCQ (months)
|
13.58 (6.94, 25.19)
|
15.49 (7.31, 25.87)
|
0.771
|
11.10 (5.77, 21.72)
|
8.88 (3.01, 15.99)
|
0.115
|
Time to SACQ/SQCQb (months)
|
23.88 (13.03, 50.68)
|
22.07 (12.16, 50.62)
|
0.562
|
21.0 (11.85, 58.65)
|
17.28 (9.84, 36.53)
|
0.241
|
Dose of corticosteroids at the start of SACQ/SQCQ
|
7.5 (5.0, 7.5)
|
7.5 (6.25, 7.5)
|
0.096
|
7.5 (5.0, 7.5)
|
7.5 (5.0, 7.5)
|
0.608
|
Taking antimalarials at the start of SACQ/SQCQ
|
40/56 (71.4%)
|
90/114 (78.9%)
|
0.277
|
22/29
|
132/158
|
0.319
|
Taking immunosuppressants at the start of SACQ/SQCQ
|
29/56 (51.8%)
|
67/114 (58.8%)
|
0.414
|
15/29
|
84/158
|
0.886
|
Dose of corticosteroidsc (mg) when relapsed or at the end of follow-up
|
5.0 (2.81,7.5)
|
3.75 (1.25, 5.0)
|
0.011
|
5.0 (0, 5.0)
|
3.75 (1.25, 5.0)
|
0.489
|
Taking antimalarials when relapsed or at the end of follow-up
|
36/56 (64.3%)
|
97/114 (85.1%)
|
0.002
|
17/29 (58.6%)
|
135/158 (85.4%)
|
0.001
|
Taking immunosuppressants when relapsed or at the end of follow-up
|
23/56 (41.1%)
|
69/114 (60.5%)
|
0.017
|
10/29 (34.5%)
|
87/158 (55.1%)
|
0.041
|
Anti-dsDNA (+)
|
41/56 (73.2%)
|
96/114 (84.2%)
|
0.101
|
—
|
—
|
—
|
Hypocomplementemia
|
26/56 (46.4%)
|
36/114 (31.6%)
|
0.064
|
—
|
—
|
—
|
Symptoms at initial diagnosis.
|
LN
|
16/56 (28.6%)
|
46/114 (40.4%)
|
0.175
|
10/29 (34.5%)
|
58/158 (36.7%)
|
0.819
|
NPSLE
|
2/56 (3.6%)
|
6/114 (5.3%)
|
1.000
|
1/29 (3.4%)
|
10/158 (6.3%)
|
0.860
|
Thrombocytopenia
|
9/56 (16.1%)
|
14/114 (12.3%)
|
0.485
|
6/29 (20.7%)
|
30/158 (19.0%)
|
0.831
|
Hemolytic anemia
|
5/56 (8.9%)
|
9/114 (7.9%)
|
0.776
|
1/29 (3.4%)
|
13/158 (8.2%)
|
0.606
|
Pulmonary hypertension
|
3/56 (5.4%)
|
1/114 (0.9%)
|
0.105
|
1/29 (3.4%)
|
4/158 (2.5%)
|
1.000
|
Myocardial involvement
|
0/56 (0)
|
0/114 (0)
|
NA
|
0/29 (0)
|
3/158 (1.9%)
|
1.000
|
ILD
|
2/56 (3.6%)
|
1/114 (0.9%)
|
0.253
|
0/29 (0)
|
6/158 (3.8%)
|
0.622
|
Alveolar hemorrhage
|
0/56 (0)
|
0/114 (0)
|
NA
|
0/29 (0)
|
0/29 (0)
|
NA
|
Smooth muscle involvement
|
0/56 (0)
|
6/114 (5.3%)
|
0.179
|
0/29 (0)
|
5/158 (3.2%)
|
0.730
|
Polyserositis
|
2/56 (3.6%)
|
6/114 (5.3%)
|
1.000
|
1/29 (3.4%)
|
7/158 (4.4%)
|
1.000
|
APS
|
2/56 (3.6%)
|
5/114 (4.4%)
|
1.000
|
1/29 (3.4%)
|
4/158 (2.5%)
|
1.000
|
TTP or TMA
|
0/56 (0)
|
0/114 (0)
|
NA
|
0/29 (0)
|
0/29 (0)
|
NA
|
Secondary SS
|
5/56 (8.9%)
|
14/114 (12.3%)
|
0.611
|
3/29 (10.3%)
|
22/158 (13.9%)
|
0.823
|